183 related articles for article (PubMed ID: 36117308)
21. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer.
Wang D; Yang Y; Jin L; Wang J; Zhao X; Wu G; Zhang J; Kou T; Yao H; Zhang Z
J Cancer; 2019; 10(19):4552-4563. PubMed ID: 31528219
[No Abstract] [Full Text] [Related]
22. A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer.
Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Murono K; Watanabe T
Acta Oncol; 2017 May; 56(5):634-638. PubMed ID: 27885879
[TBL] [Abstract][Full Text] [Related]
23. External quality assessment for detection of colorectal cancer by Septin9 DNA methylation in clinical laboratories.
Chang L; Wang D; Han Y; Diao Z; Chen Y; Li J; Zhang R
Clin Chim Acta; 2024 Jan; 552():117663. PubMed ID: 38008152
[TBL] [Abstract][Full Text] [Related]
24. The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection.
Ying HQ; Liao YC; Sun F; Peng HX; Cheng XX
J Inflamm Res; 2021; 14():115-129. PubMed ID: 33500648
[TBL] [Abstract][Full Text] [Related]
25. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.
Yang XQ; Chen C; Peng CW; Liu SP; Li Y
Med Oncol; 2012 Jun; 29(2):1030-6. PubMed ID: 21553105
[TBL] [Abstract][Full Text] [Related]
26. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
[TBL] [Abstract][Full Text] [Related]
27. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer.
Song L; Guo S; Wang J; Peng X; Jia J; Gong Y; Yang B; Xiao W; Dong C; Liu H; Li Y
Biomark Med; 2018 Sep; 12(9):961-973. PubMed ID: 30043648
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II-III Colorectal Cancer: A Retrospective Multi-Center Cohort Study.
Liu L; Pang X; Zhao K; Chen Y; Li Y; You R; Xu T; Liu M; Wu L; Li Z; Pu H
Int J Gen Med; 2023; 16():3311-3322. PubMed ID: 37554705
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Significance of Septin 9 and Colon Cancer Specific Antigen-2 (CCSA-2) in Colorectal Cancer.
Abd El Kader L; Soliman AH; Salem SE; Akel SY; Ibrahim NH
Asian Pac J Cancer Prev; 2023 Mar; 24(3):1027-1036. PubMed ID: 36974558
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of plasma methylated SEPT 9 gene in patients with primary liver cancer].
He N; Feng G; Zhang FN; Hao S; Li R; Zhao ZQ; Tian YW; Yan HL
Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):265-270. PubMed ID: 37137852
[No Abstract] [Full Text] [Related]
31. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
32. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
[TBL] [Abstract][Full Text] [Related]
33. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
35. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
36. Plasma Methylated SEPT9 as a Novel Biomarker for Predicting Liver Metastasis in Colorectal Cancer.
Yu M; Yang C; Wang S; Shi Y; Wang J; Meng C; Xue L; Chen Z
Mol Biotechnol; 2023 Aug; ():. PubMed ID: 37608077
[TBL] [Abstract][Full Text] [Related]
37. Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery.
Ma ZY; Law WL; Ng EKO; Chan CSY; Lau KS; Cheng YY; Shin VY; Kwong A; Leung WK
Sci Rep; 2019 Jul; 9(1):10326. PubMed ID: 31316143
[TBL] [Abstract][Full Text] [Related]
38. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon.
Lee HS; Hwang SM; Kim TS; Kim DW; Park DJ; Kang SB; Kim HH; Park KU
Transl Oncol; 2013 Jun; 6(3):290-6. PubMed ID: 23730408
[TBL] [Abstract][Full Text] [Related]
39. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
[TBL] [Abstract][Full Text] [Related]
40. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
